— Financial reporting — Consolidated income statement

Consolidated income statement

January 1 – June 30

millions of CHF	Notes	2023	2022 1)
Revenue	3	248.1	250.6
Cost of goods sold		–166.1	–151.4
Gross profit		82.0	99.2
Selling and administrative expenses		–57.2	–52.5
Research and development expenses		–12.9	–12.3
Other operating income/(expenses), net	5	2.5	–17.6
Operating income		14.5	16.9
Interest income	6	0.3	0.0
Interest expenses	6	–4.2	–3.0
Other financial income/(expenses), net	6	–1.6	–0.2
Income before tax expenses		9.0	13.7
Income tax expenses	7	–1.7	–4.5
Total net income		7.3	9.2

Earnings per share (in CHF)
Basic earnings per share		0.18	0.23
Diluted earnings per share		0.18	0.22

1) The numbers as of June 30, 2022, have been adjusted following the deconsolidation of medmix Poland. A reconciliation to the previously published numbers is provided in note 14.